The Expression of Basal Cytokeratins in Breast Cancers

Dr. Vidhya Lakshmi S; Dr. Seyed Rabia

Authors

Dr. Vidhya Lakshmi S
Dr. Seyed Rabia

Keywords:

triple negative breast cancers, cytokeratin 5/6, basal-like breast carcinoma

Abstract

Abstract not found

Downloads

How to Cite

The Expression of Basal Cytokeratins in Breast Cancers. (2017). Global Journal of Medical Research, 17(27), 17-21. https://medicalresearchjournal.org/index.php/GJMR/article/view/

Download Citation

References

Emad Rakha, Jorge Reis-Filho (2009) Basal-like Breast Carcinoma: From Expression Profiling to Routine Practice. 133(6), 860-868. https://doi.org/10.5858/133.6.860

http://globocan.iarc.fr/old/factsheet.asp

M. Heatley, P. Maxwell, C. Whiteside, P. Toner (1994) Cytokeratin intermediate filament expression in benign and malignant breast disease. 48(1), 26-32. https://doi.org/10.1136/jcp.48.1.26

D. Barnes, A. Hanby (2001) Oestrogen and progesterone receptors in breast cancer: past, present and future. 38(3), 271-274. https://doi.org/10.1046/j.1365-2559.2001.01060.x

A. Glass, J. Lacey, J. Carreon, R. Hoover (2007) Breast Cancer Incidence, 1980 2006: Combined Roles of Menopausal Hormone Therapy, Screening Mammography, and Estrogen Receptor Status. 99(15), 1152-1161.

Laakso M, Tanner M, Nilsson J (2006) Basoluminal Carcinoma: A New Biologically and Prognostically Distinct Entity Between Basal and Luminal Breast Cancer. 12, 4185-4191.

Sarrio D, Rodriguez-Pinilla SM, Hardisson D (2008) Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype. 68(4), 989-997. https://doi.org/10.1158/0008-5472.can-07-2017

Doval DC, Sharma A, Sinha R, Kumar K, Dewan AK, Chaturvedi H Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in South India. 12, 625-629.

Harvey JM, Clark GM, Osbourne CK, Allred DC (1999) Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer. 17(5), 1474-1481.

Gown AM (2008) Current issues in ER and HER2 testing by IHC in breast cancer. 21, S8-S15.

J. Dolle Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years. 18(4), 1157-1166.

S. Clark, J. Warwick, R. Carpenter, R. Bowen, S. Duffy, J. Jones (2011) Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. 104, 120-127.

O. Torsten, Forrest Nielsen, Kristin Hsu, Maggie Jensen, Gamze Cheang, Zhiyuan Karaca, Tina Hu, Hernandez-Boussard (2004) Nielsen, Forrest D Hsu, Kristin Jensen, Maggie Cheang, Gamze Karaca, Zhiyuan Hu, Tina Hernandez-Boussard et al Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. 10, 5367-5374.